Scientists based in Vienna unveil the complex molecular structure that causes lethal infections by Mycobacterium tuberculosis (Mtb). Their findings might have implications for potential therapies against antibiotic-resistant tuberculosis.
In a paper published this week in Nature Microbiology, an international team of scientists across Europe, including IMP (Institute of Molecular Pathology) and IMBA (Institute of Molecular Biotechnology of the Austrian Academy of Sciences) group leader Thomas Marlovits, describe the overall architecture of an assembly of proteins known as Type VII (T7SS) secretion systems found in a group of bacteria which cause diseases such as tuberculosis.
“We could identify a unique architectural principle that potentially reveals a novel molecular mechanism of T7SS, a protein complex located in the cell membrane of bacteria”, says molecular biologist and biochemist Thomas Marlovits, who led the structural analysis by electron microscopy and who is also Professor at the Medical Center Hamburg-Eppendorf (UKE) and deputy director at the Centre for Structural Systems Biology (CSSB) in Hamburg.
“This new system will allow us to further investigate the biology of the bacterium that causes tuberculosis as Mtb relies heavily on T7SS to transport molecules across its cell membrane upon infection, disarming and damaging the host cell.” Relying heavily on large-scale facilities for structural data but also Mtb genetics, the team had joined forces with researchers at EMBL Hamburg and at the Vrije Universiteit Amsterdam.
New drugs are urgently needed in the fight against tuberculosis as the bacteria responsible for causing the disease become increasingly resistant to current antibiotics. According to the World Health Organisation, tuberculosis resulted in 1.8 million deaths and 10.4 million new infections in 2015, making it one of the top 10 causes of death in humans worldwide.
The bacterium responsible has a complex biology and a comprehensive understanding of this is crucial to inform the development of new drugs.
T7SS-systems play a key role in tuberculosis infections and might present important targets for much needed new drugs: blocking these systems could prevent the bacteria from bursting the host cells and could thus alleviate the infection.
Thomas Marlovits illustrates the unique molecular architecture of the T7SS transport system: “In total, five T7SS systems are found in mycobacteria. Known as ESX-1 to ESX-5, these systems are likely all very similar but transport specific molecules. In our study, we could show that the mycobacterial T7SS structure sits exclusively in the inner bacterial membrane.”
In addition to the core body of T7SS, some of the proteins extend down into the bacterial cell. The team collected Small Angle X-ray Scattering (SAXS) data at the EMBL SAXS beamline on the DESY campus in Hamburg to help understand what they look like and how these parts of the secretion system might move. “We believe these arm-like proteins help to move the molecules of different shapes and sizes from the inside of the bacterial cell towards the pore of the secretion system for them to be transported out of the cell,” says first author Kate Beckham from EMBL Hamburg.
Now further biochemical and genetic experiments will be carried out to support the structural data and to provide in vivo insights into the components required for assembly of the T7 secretion system.
Beckham K.S.H et al. Structure of a mycobacterial type VII secretion system membrane complex. Nature Microbiology, 2017. DOI: 10.1038/nmicrobiol.2017.47.
About the IMP
The Research Institute of Molecular Pathology (IMP) in Vienna is a basic biomedical research institute largely sponsored by Boehringer Ingelheim. With over 200 scientists from 37 nations, the IMP is committed to scientific discovery of fundamental molecular and cellular mechanisms underlying complex biological phenomena. Research areas include cell and molecular biology, neurobiology, disease mechanisms and computational biology.
IMBA - Institute of Molecular Biotechnology is one of the leading biomedical research institutes in Europe focusing on cutting-edge functional genomics and stem cell technologies. IMBA is located at the Vienna Biocenter, the vibrant cluster of universities, research institutes and biotech companies in Austria. IMBA is a subsidiary of the Austrian Academy of Sciences, the leading national sponsor of non-university academic research.
Media Contact at IMP
Dr. Heidemarie Hurtl
Research Institute of Molecular Pathology
+43 (0)1 79730 3625
Media Contact at IMBA
IMBA - Institute of Molecular Biotechnology
+43 (1) 790 44-3628
Ines Méhu-Blantar | idw - Informationsdienst Wissenschaft
Gut microbiome regulates the intestinal immune system, researchers find
19.12.2018 | Brown University
Greener days ahead for carbon fuels
19.12.2018 | DOE/Lawrence Berkeley National Laboratory
Different eras of civilization are defined by the discovery of new materials, as new materials drive new capabilities. And yet, identifying the best material...
Researchers from the University of Basel have reported a new method that allows the physical state of just a few atoms or molecules within a network to be controlled. It is based on the spontaneous self-organization of molecules into extensive networks with pores about one nanometer in size. In the journal ‘small’, the physicists reported on their investigations, which could be of particular importance for the development of new storage devices.
Around the world, researchers are attempting to shrink data storage devices to achieve as large a storage capacity in as small a space as possible. In almost...
The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.
Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...
What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...
12.12.2018 | Event News
10.12.2018 | Event News
06.12.2018 | Event News
19.12.2018 | Materials Sciences
19.12.2018 | Materials Sciences
19.12.2018 | Life Sciences